Research progress on the pathogenesis of chronic obstructive pulmonary disease complicated with lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Anying ¹ , LI Zhiwei ¹ , SUN Dianhan ¹ , CHEN Yong ² , WU Jun ² ,  SHU Yusheng ²

1. Dalian Medical University, Dalian, 116044, Liaoning, P. R. China;
2. Department of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou, 225009, Jiangsu, P. R. China;

Corresponding author：

SHU Yusheng, Email: 18051061999@yzu.edu.cn

Keywords：

Chronic obstructive pulmonary disease; lung cancer; pathogenesis; genetic inheritance; review

DOI：

10.7507/1007-4848.202307030

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Chronic obstructive pulmonary disease (COPD), which predominantly affects middle-aged and elderly individuals, is associated with a significantly reduced quality of life and often triggers various other pulmonary conditions. Lung cancer, as one of the most prevalent and deadly pulmonary malignancies worldwide, poses a severe threat to global public health. The risk of developing lung cancer is markedly higher in COPD patients compared to the general population, indicating numerous associations between the two conditions that warrant in-depth investigation. Although a substantial body of research has explored the relationship between COPD and lung cancer, studies focusing on the molecular mechanisms underlying their connection remain limited. This article reviews the latest research progress on the mechanisms of COPD complicated by lung cancer from four perspectives: the role of chronic pulmonary inflammation, programmed cell death, genetic and molecular interactions, and dysbiosis of the pulmonary microbiome. The aim of this article is to provide new insights and references for the prevention and therapeutic strategies of COPD complicated with lung cancer.

Citation： LI Anying, LI Zhiwei, SUN Dianhan, CHEN Yong, WU Jun, SHU Yusheng. Research progress on the pathogenesis of chronic obstructive pulmonary disease complicated with lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(6): 855-862. doi: 10.7507/1007-4848.202307030 Copy

1.	Forder A, Zhuang R, Souza VGP, et al. Mechanisms contributing to the comorbidity of COPD and lung cancer. Int J Mol Sci, 2023, 24(3): 2859.
2.	McRobbie H, Kwan B. Tobacco use disorder and the lungs. Addiction, 2021, 116(9): 2559-2571.
3.	Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer, 2013, 13(4): 233-245.
4.	Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009, 34(2): 380-386.
5.	Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Arch Bronconeumol, 2023, 59(4): 232-248.
6.	GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: An update from the Global Burden of Disease Study 2019. EClinicalMedicine, 2023, 59: 101936.
7.	Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: Evaluation and management. Med Clin North Am, 2019, 103(3): 453-461.
8.	Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: Risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med, 2022, 10(5): 497-511.
9.	Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet, 2005, 365(9478): 2225-2236.
10.	Zhang S, Pang K, Feng X, et al. Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma. Sci Rep, 2022, 12(1): 13214.
11.	Lancaster HL, Heuvelmans MA, Oudkerk M. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research. J Intern Med, 2022, 292(1): 68-80.
12.	Yang SR, Schultheis AM, Yu H, et al. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol, 2022, 84: 184-198.
13.	de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease: Incidence and predicting factors. Am J Respir Crit Care Med, 2011, 184(8): 913-919.
14.	赵艳青, 侯明霞, 张彩苹. 慢性阻塞性肺疾病对肺癌免疫治疗临床疗效影响的分析. 临床肺科杂志, 2023, 28(9): 1304-1309.Zhao YQ, Hou MX, Zhang CP. Analysis of the clinical effect of the chronic obstructive pulmonary disease on immunotherapy of the lung cancer. J Clin Pulm Med, 2023, 28(9): 1304-1309.
15.	张瑶, 刘学军. 慢性阻塞性肺疾病合并肺癌发病机制的研究进展. 中华老年多器官疾病杂志, 2022, 21(1): 76-80.Zhang Y, Liu XJ. Research progress of pathogenesis of chronic obstructive pulmonary disease complicated with lung cancer. Chin J Mult Organ Dis Elder, 2022, 21(1): 76-80.
16.	王娅洁, 吴爽爽, 储江, 等. 肺部微生物组通过炎症反应介导慢性阻塞性肺疾病转化为肺癌的研究进展. 遗传, 2021, 43(1): 30-39.Wang YJ, Wu SS, Chu J, et al. Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation. Hereditas, 2021, 43(1): 30-39.
17.	魏智民, 孙玉发, 李刚, 等. 癌症相关性炎症与肿瘤微环境相关研究进展. 中国肿瘤临床, 2018, 45(21): 1117-1121.Wei ZM, Sun YF, Li G, et al. Advances of research in canner-associated inflammation and tumor microenvironments. Chin J Clin Oncol, 2018, 45(21): 1117-1121.
18.	Fan T, Li S, Xiao C, et al. CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition. Int J Biol Sci, 2022, 18(11): 4275-4288.
19.	Chang YS, Tu SJ, Chen YC, et al. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res, 2021, 22(1): 3.
20.	Shukla SD, Walters EH, Simpson JL, et al. Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease. Respirology, 2020, 25(1): 53-63.
21.	Baek EB, Kim YJ, Rho JH, et al. Anti-inflammatory effect of Gyeji-tang in a chronic obstructive pulmonary disease mouse model induced by cigarette smoke and lipopolysaccharide. Pharm Biol, 2022, 60(1): 2040-2048.
22.	Aquilina NJ, Havel CM, Harrison RM, et al. Determination of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) arising from tobacco smoke in airborne particulate matter. Environ Int, 2022, 158: 106992.
23.	Liu CH, Chen Z, Chen K, et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy. Cancer Res, 2021, 81(1): 144-157.
24.	沈诚, 车国卫. 炎症因子与肺癌研究进展. 中华肿瘤防治杂志, 2014, 21(2): 157-160.Shen C, Che GW. Research situation of inflammation factors and lung cancer. Chin J Cancer Prev Treat, 2014, 21(2): 157-160.
25.	Budisan L, Zanoaga O, Braicu C, et al. Links between infections, lung cancer, and the immune system. Int J Mol Sci, 2021, 22(17): 9394.
26.	Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol, 2017, 12(8): 1268-1279.
27.	Tamura T, Miyazaki K, Satoh H. Features of COPD as predictors of lung cancer. Chest, 2018, 154(3): 720-721.
28.	García-Rio F, Romero D, Lores V, et al. Dynamic hyperinflation, arterial blood oxygen, and airway oxidative stress in stable patients with COPD. Chest, 2011, 140(4): 961-969.
29.	Zamarrón E, Prats E, Tejero E, et al. Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease. Lung Cancer, 2019, 128: 40-46.
30.	Yu S, Jia J, Zheng J, et al. Recent progress of ferroptosis in lung diseases. Front Cell Dev Biol, 2021, 9: 789517.
31.	Oliveri V. Selective targeting of cancer cells by copper ionophores: An overview. Front Mol Biosci, 2022, 9: 841814.
32.	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5): 1060-1072.
33.	Xia H, Wu Y, Zhao J, et al. N6-methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2. Cell Death Differ, 2023, 30(5): 1293-1304.
34.	Qiao D, Hu C, Li Q, et al. Circ-RBMS1 knockdown alleviates cse-induced apoptosis, inflammation and oxidative stress via up-regulating FBXO11 through miR-197-3p in 16HBE cells. Int J Chron Obstruct Pulmon Dis, 2021, 16: 2105-2118.
35.	Zhang W, Sun Y, Bai L, et al. RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J Clin Invest, 2021, 131(22): e152067.
36.	Li R, Li X, Hagood J, et al. Myofibroblast contraction is essential for generating and regenerating the gas-exchange surface. J Clin Invest, 2020, 130(6): 2859-2871.
37.	Wang Y, Duan H, Zhang J, et al. YAP1 protects against PM2.5-induced lung toxicity by suppressing pyroptosis and ferroptosis. Ecotoxicol Environ Saf, 2023, 253: 114708.
38.	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261.
39.	Fei Q, Weng X, Liu K, et al. The relationship between metal exposure and chronic obstructive pulmonary disease in the general US population: NHANES 2015-2016. Int J Environ Res Public Health, 2022, 19(4): 2085.
40.	Healy C, Munoz-Wolf N, Strydom J, et al. Nutritional immunity: The impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respir Res, 2021, 22(1): 133.
41.	Chen Y, Tang L, Huang W, et al. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Front Endocrinol (Lausanne), 2022, 13: 963220.
42.	Li X, Dai Z, Liu J, et al. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer. Front Genet, 2022, 13: 969856.
43.	Cai Y, Liu R, Lu X, et al. Correlation in gene expression between the aggravation of chronic obstructive pulmonary disease and the occurrence of complications. Bioengineered, 2020, 11(1): 1245-1257.
44.	Zhong F, Lin Y, Zhao L, et al. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: From mechanisms to therapeutics. Br J Cancer, 2023, 129(1): 24-37.
45.	Córdoba-Lanús E, Domínguez de-Barros A, Oliva A, et al. Circulating miR-206 and miR-1246 as markers in the early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. Int J Mol Sci, 2023, 24(15): 12437.
46.	Fujimoto J, Nunomura-Nakamura S, Liu Y, et al. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer, 2017, 141(8): 1589-1599.
47.	Treekitkarnmongkol W, Hassane M, Sinjab A, et al. Augmented lipocalin-2 is associated with chronic obstructive pulmonary disease and counteracts lung adenocarcinoma development. Am J Respir Crit Care Med, 2021, 203(1): 90-101.
48.	Wang Q, Li S, Tang X, et al. Lipocalin 2 protects against escherichia coli infection by modulating neutrophil and macrophage function. Front Immunol, 2019, 10: 2594.
49.	Zhou RH, Zhang JT, Chen C, et al. Identification of CDC5L as bridge gene between chronic obstructive pulmonary disease and lung adenocarcinoma. Epigenomics, 2020, 12(17): 1515-1529.
50.	Conlon TM, John-Schuster G, Heide D, et al. Inhibition of LTβR signalling activates WNT-induced regeneration in lung. Nature, 2020, 588(7836): 151-156.
51.	Koerner L, Schmiel M, Yang TP, et al. NEMO- and RelA-dependent NF-κB signaling promotes small cell lung cancer. Cell Death Differ, 2023, 30(4): 938-951.
52.	Su X, Liu N, Wu W, et al. Comprehensive analysis of prognostic value and immune infiltration of kindlin family members in non-small cell lung cancer. BMC Med Genomics, 2021, 14(1): 119.
53.	Su X, Chen J, Lin X, et al. FERMT3 mediates cigarette smoke-induced epithelial-mesenchymal transition through Wnt/β-catenin signaling. Respir Res, 2021, 22(1): 286.
54.	Verdura S, Encinar JA, Teixidor E, et al. Silibinin overcomes EMT-driven lung cancer resistance to new-generation ALK inhibitors. Cancers (Basel), 2022, 14(24): 6101.
55.	Ahmad S, Manzoor S, Siddiqui S, et al. Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19. Semin Cancer Biol, 2022, 83: 384-398.
56.	Kumar S, Gonzalez EA, Rameshwar P, et al. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel), 2020, 12(12): 3657.
57.	Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, et al. The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomed Pharmacother, 2022, 148: 112735.
58.	Rezaei S, Mahjoubin-Tehran M, Aghaee-Bakhtiari SH, et al. Autophagy-related MicroRNAs in chronic lung diseases and lung cancer. Crit Rev Oncol Hematol, 2020, 153: 103063.
59.	Zeng Z, He S, Lu J, et al. MicroRNA-21 aggravates chronic obstructive pulmonary disease by promoting autophagy. Exp Lung Res, 2018, 44(2): 89-97.
60.	Li S, Zeng X, Ma R, et al. MicroRNA-21 promotes the proliferation, migration and invasion of non-small cell lung cancer A549 cells by regulating autophagy activity via AMPK/ULK1 signaling pathway. Exp Ther Med, 2018, 16(3): 2038-2045.
61.	Li Y, Yin Z, Fan J, et al. The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal Transduct Target Ther, 2019, 4: 47.
62.	Sun L, Xu A, Li M, et al. Effect of methylation status of lncRNA-MALAT1 and microRNA-146a on pulmonary function and expression level of COX2 in patients with chronic obstructive pulmonary disease. Front Cell Dev Biol, 2021, 9: 667624.
63.	Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol, 2018, 233(9): 6679-6688.
64.	Li N, Liu Y, Cai J. LncRNA MIR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease. Biomed Pharmacother, 2019, 117: 109015.
65.	Guo Y, Li G, Xu M, et al. A lncRNA signature of tumor-infiltrating macrophages is associated with prognosis and tumor immunity in lung adenocarcinoma. Comput Biol Med, 2022, 148: 105655.
66.	van der Werf J, Chin CV, Fleming NI. SnoRNA in cancer progression, metastasis and immunotherapy response. Biology (Basel), 2021, 10(8): 809.
67.	Wang K, Wang S, Zhang Y, et al. SNORD88C guided 2'-O-methylation of 28S rRNA regulates SCD1 translation to inhibit autophagy and promote growth and metastasis in non-small cell lung cancer. Cell Death Differ, 2023, 30(2): 341-355.
68.	Liu X, Ali MK, Zhao L, et al. The emerging diagnostic and therapeutic roles of small nucleolar RNAs in lung diseases. Biomed Pharmacother, 2023, 161: 114519.
69.	Bratkovič T, Božič J, Rogelj B. Functional diversity of small nucleolar RNAs. Nucleic Acids Res, 2020, 48(4): 1627-1651.
70.	Ahmad S, Zhang XL, Ahmad A. Epigenetic regulation of pulmonary inflammation. Semin Cell Dev Biol, 2024, 154(Pt C): 346-354.
71.	Hussain S, Tulsyan S, Dar SA, et al. Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy. Semin Cancer Biol, 2022, 83: 441-451.
72.	Li P, Liu S, Du L, et al. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer. Clin Epigenetics, 2022, 14(1): 118.
73.	He LX, Tang ZH, Huang QS, et al. DNA methylation: A potential biomarker of chronic obstructive pulmonary disease. Front Cell Dev Biol, 2020, 8: 585.
74.	Aggarwal T, Wadhwa R, Thapliyal N, et al. Oxidative, inflammatory, genetic, and epigenetic biomarkers associated with chronic obstructive pulmonary disorder. J Cell Physiol, 2019, 234(3): 2067-2082.
75.	Fang Y, Qu Y, Ji L, et al. Novel blood-based FUT7 DNA methylation is associated with lung cancer: Especially for lung squamous cell carcinoma. Clin Epigenetics, 2022, 14(1): 167.
76.	Zhang G, Wang Z, Song P, et al. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. EPMA J, 2022, 13(4): 649-669.
77.	Günes Günsel G, Conlon TM, Jeridi A, et al. The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nat Commun, 2022, 13(1): 1303.
78.	Cheng D, He Z, Zheng L, et al. PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2. Onco Targets Ther, 2018, 11: 4869-4876.
79.	Su Y, Han W, Kovacs-Kasa A, et al. HDAC6 Activates ERK in airway and pulmonary vascular remodeling of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 2021, 65(6): 603-614.
80.	Wattanathamsan O, Chantaravisoot N, Wongkongkathep P, et al. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction. J Biomed Sci, 2023, 30(1): 4.
81.	Zhao L, Luo JL, Ali MK, et al. The human respiratory microbiome: Current understandings and future directions. Am J Respir Cell Mol Biol, 2023, 68(3): 245-255.
82.	木亚莎尔·吐逊江, 王雨琳, 曹洪丽. 慢性阻塞性肺疾病合并肺癌共同发病机制. 中国组织化学与细胞化学杂志, 2022, 31(4): 412-416.Muyashaer TXJ, Wang YL, Cao HL. The common pathogenesis of chronic obstructive pulmonary disease with lung cancer. Chin J Histochem Cytochem, 2022, 31(4): 412-416.
83.	Liang W, Yang Y, Gong S, et al. Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease. Cell Host Microbe, 2023, 31(6): 1054-1070.
84.	Madapoosi SS, Cruickshank-Quinn C, Opron K, et al. Lung microbiota and metabolites collectively associate with clinical outcomes in milder stage chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2022, 206(4): 427-439.
85.	Cameron SJS, Lewis KE, Huws SA, et al. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One, 2017, 12(5): e0177062.
86.	Kong LY, Chen XY, Lu X, et al. Association of lung-intestinal microecology and lung cancer therapy. Chin Med, 2023, 18(1): 37.
87.	Wang W, Liang X, Kong H, et al. Correlation analysis of lung mucosa-colonizing bacteria with clinical features reveals metastasis-associated bacterial community structure in non-small cell lung cancer patients. Respir Res, 2023, 24(1): 129.

1. Forder A, Zhuang R, Souza VGP, et al. Mechanisms contributing to the comorbidity of COPD and lung cancer. Int J Mol Sci, 2023, 24(3): 2859.
2. McRobbie H, Kwan B. Tobacco use disorder and the lungs. Addiction, 2021, 116(9): 2559-2571.
3. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer, 2013, 13(4): 233-245.
4. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009, 34(2): 380-386.
5. Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Arch Bronconeumol, 2023, 59(4): 232-248.
6. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: An update from the Global Burden of Disease Study 2019. EClinicalMedicine, 2023, 59: 101936.
7. Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: Evaluation and management. Med Clin North Am, 2019, 103(3): 453-461.
8. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: Risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med, 2022, 10(5): 497-511.
9. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet, 2005, 365(9478): 2225-2236.
10. Zhang S, Pang K, Feng X, et al. Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma. Sci Rep, 2022, 12(1): 13214.
11. Lancaster HL, Heuvelmans MA, Oudkerk M. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research. J Intern Med, 2022, 292(1): 68-80.
12. Yang SR, Schultheis AM, Yu H, et al. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol, 2022, 84: 184-198.
13. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease: Incidence and predicting factors. Am J Respir Crit Care Med, 2011, 184(8): 913-919.
14. 赵艳青, 侯明霞, 张彩苹. 慢性阻塞性肺疾病对肺癌免疫治疗临床疗效影响的分析. 临床肺科杂志, 2023, 28(9): 1304-1309.Zhao YQ, Hou MX, Zhang CP. Analysis of the clinical effect of the chronic obstructive pulmonary disease on immunotherapy of the lung cancer. J Clin Pulm Med, 2023, 28(9): 1304-1309.
15. 张瑶, 刘学军. 慢性阻塞性肺疾病合并肺癌发病机制的研究进展. 中华老年多器官疾病杂志, 2022, 21(1): 76-80.Zhang Y, Liu XJ. Research progress of pathogenesis of chronic obstructive pulmonary disease complicated with lung cancer. Chin J Mult Organ Dis Elder, 2022, 21(1): 76-80.
16. 王娅洁, 吴爽爽, 储江, 等. 肺部微生物组通过炎症反应介导慢性阻塞性肺疾病转化为肺癌的研究进展. 遗传, 2021, 43(1): 30-39.Wang YJ, Wu SS, Chu J, et al. Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation. Hereditas, 2021, 43(1): 30-39.
17. 魏智民, 孙玉发, 李刚, 等. 癌症相关性炎症与肿瘤微环境相关研究进展. 中国肿瘤临床, 2018, 45(21): 1117-1121.Wei ZM, Sun YF, Li G, et al. Advances of research in canner-associated inflammation and tumor microenvironments. Chin J Clin Oncol, 2018, 45(21): 1117-1121.
18. Fan T, Li S, Xiao C, et al. CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition. Int J Biol Sci, 2022, 18(11): 4275-4288.
19. Chang YS, Tu SJ, Chen YC, et al. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res, 2021, 22(1): 3.
20. Shukla SD, Walters EH, Simpson JL, et al. Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease. Respirology, 2020, 25(1): 53-63.
21. Baek EB, Kim YJ, Rho JH, et al. Anti-inflammatory effect of Gyeji-tang in a chronic obstructive pulmonary disease mouse model induced by cigarette smoke and lipopolysaccharide. Pharm Biol, 2022, 60(1): 2040-2048.
22. Aquilina NJ, Havel CM, Harrison RM, et al. Determination of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) arising from tobacco smoke in airborne particulate matter. Environ Int, 2022, 158: 106992.
23. Liu CH, Chen Z, Chen K, et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy. Cancer Res, 2021, 81(1): 144-157.
24. 沈诚, 车国卫. 炎症因子与肺癌研究进展. 中华肿瘤防治杂志, 2014, 21(2): 157-160.Shen C, Che GW. Research situation of inflammation factors and lung cancer. Chin J Cancer Prev Treat, 2014, 21(2): 157-160.
25. Budisan L, Zanoaga O, Braicu C, et al. Links between infections, lung cancer, and the immune system. Int J Mol Sci, 2021, 22(17): 9394.
26. Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol, 2017, 12(8): 1268-1279.
27. Tamura T, Miyazaki K, Satoh H. Features of COPD as predictors of lung cancer. Chest, 2018, 154(3): 720-721.
28. García-Rio F, Romero D, Lores V, et al. Dynamic hyperinflation, arterial blood oxygen, and airway oxidative stress in stable patients with COPD. Chest, 2011, 140(4): 961-969.
29. Zamarrón E, Prats E, Tejero E, et al. Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease. Lung Cancer, 2019, 128: 40-46.
30. Yu S, Jia J, Zheng J, et al. Recent progress of ferroptosis in lung diseases. Front Cell Dev Biol, 2021, 9: 789517.
31. Oliveri V. Selective targeting of cancer cells by copper ionophores: An overview. Front Mol Biosci, 2022, 9: 841814.
32. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5): 1060-1072.
33. Xia H, Wu Y, Zhao J, et al. N6-methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2. Cell Death Differ, 2023, 30(5): 1293-1304.
34. Qiao D, Hu C, Li Q, et al. Circ-RBMS1 knockdown alleviates cse-induced apoptosis, inflammation and oxidative stress via up-regulating FBXO11 through miR-197-3p in 16HBE cells. Int J Chron Obstruct Pulmon Dis, 2021, 16: 2105-2118.
35. Zhang W, Sun Y, Bai L, et al. RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J Clin Invest, 2021, 131(22): e152067.
36. Li R, Li X, Hagood J, et al. Myofibroblast contraction is essential for generating and regenerating the gas-exchange surface. J Clin Invest, 2020, 130(6): 2859-2871.
37. Wang Y, Duan H, Zhang J, et al. YAP1 protects against PM2.5-induced lung toxicity by suppressing pyroptosis and ferroptosis. Ecotoxicol Environ Saf, 2023, 253: 114708.
38. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261.
39. Fei Q, Weng X, Liu K, et al. The relationship between metal exposure and chronic obstructive pulmonary disease in the general US population: NHANES 2015-2016. Int J Environ Res Public Health, 2022, 19(4): 2085.
40. Healy C, Munoz-Wolf N, Strydom J, et al. Nutritional immunity: The impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respir Res, 2021, 22(1): 133.
41. Chen Y, Tang L, Huang W, et al. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Front Endocrinol (Lausanne), 2022, 13: 963220.
42. Li X, Dai Z, Liu J, et al. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer. Front Genet, 2022, 13: 969856.
43. Cai Y, Liu R, Lu X, et al. Correlation in gene expression between the aggravation of chronic obstructive pulmonary disease and the occurrence of complications. Bioengineered, 2020, 11(1): 1245-1257.
44. Zhong F, Lin Y, Zhao L, et al. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: From mechanisms to therapeutics. Br J Cancer, 2023, 129(1): 24-37.
45. Córdoba-Lanús E, Domínguez de-Barros A, Oliva A, et al. Circulating miR-206 and miR-1246 as markers in the early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. Int J Mol Sci, 2023, 24(15): 12437.
46. Fujimoto J, Nunomura-Nakamura S, Liu Y, et al. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer, 2017, 141(8): 1589-1599.
47. Treekitkarnmongkol W, Hassane M, Sinjab A, et al. Augmented lipocalin-2 is associated with chronic obstructive pulmonary disease and counteracts lung adenocarcinoma development. Am J Respir Crit Care Med, 2021, 203(1): 90-101.
48. Wang Q, Li S, Tang X, et al. Lipocalin 2 protects against escherichia coli infection by modulating neutrophil and macrophage function. Front Immunol, 2019, 10: 2594.
49. Zhou RH, Zhang JT, Chen C, et al. Identification of CDC5L as bridge gene between chronic obstructive pulmonary disease and lung adenocarcinoma. Epigenomics, 2020, 12(17): 1515-1529.
50. Conlon TM, John-Schuster G, Heide D, et al. Inhibition of LTβR signalling activates WNT-induced regeneration in lung. Nature, 2020, 588(7836): 151-156.
51. Koerner L, Schmiel M, Yang TP, et al. NEMO- and RelA-dependent NF-κB signaling promotes small cell lung cancer. Cell Death Differ, 2023, 30(4): 938-951.
52. Su X, Liu N, Wu W, et al. Comprehensive analysis of prognostic value and immune infiltration of kindlin family members in non-small cell lung cancer. BMC Med Genomics, 2021, 14(1): 119.
53. Su X, Chen J, Lin X, et al. FERMT3 mediates cigarette smoke-induced epithelial-mesenchymal transition through Wnt/β-catenin signaling. Respir Res, 2021, 22(1): 286.
54. Verdura S, Encinar JA, Teixidor E, et al. Silibinin overcomes EMT-driven lung cancer resistance to new-generation ALK inhibitors. Cancers (Basel), 2022, 14(24): 6101.
55. Ahmad S, Manzoor S, Siddiqui S, et al. Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19. Semin Cancer Biol, 2022, 83: 384-398.
56. Kumar S, Gonzalez EA, Rameshwar P, et al. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel), 2020, 12(12): 3657.
57. Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, et al. The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomed Pharmacother, 2022, 148: 112735.
58. Rezaei S, Mahjoubin-Tehran M, Aghaee-Bakhtiari SH, et al. Autophagy-related MicroRNAs in chronic lung diseases and lung cancer. Crit Rev Oncol Hematol, 2020, 153: 103063.
59. Zeng Z, He S, Lu J, et al. MicroRNA-21 aggravates chronic obstructive pulmonary disease by promoting autophagy. Exp Lung Res, 2018, 44(2): 89-97.
60. Li S, Zeng X, Ma R, et al. MicroRNA-21 promotes the proliferation, migration and invasion of non-small cell lung cancer A549 cells by regulating autophagy activity via AMPK/ULK1 signaling pathway. Exp Ther Med, 2018, 16(3): 2038-2045.
61. Li Y, Yin Z, Fan J, et al. The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal Transduct Target Ther, 2019, 4: 47.
62. Sun L, Xu A, Li M, et al. Effect of methylation status of lncRNA-MALAT1 and microRNA-146a on pulmonary function and expression level of COX2 in patients with chronic obstructive pulmonary disease. Front Cell Dev Biol, 2021, 9: 667624.
63. Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol, 2018, 233(9): 6679-6688.
64. Li N, Liu Y, Cai J. LncRNA MIR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease. Biomed Pharmacother, 2019, 117: 109015.
65. Guo Y, Li G, Xu M, et al. A lncRNA signature of tumor-infiltrating macrophages is associated with prognosis and tumor immunity in lung adenocarcinoma. Comput Biol Med, 2022, 148: 105655.
66. van der Werf J, Chin CV, Fleming NI. SnoRNA in cancer progression, metastasis and immunotherapy response. Biology (Basel), 2021, 10(8): 809.
67. Wang K, Wang S, Zhang Y, et al. SNORD88C guided 2'-O-methylation of 28S rRNA regulates SCD1 translation to inhibit autophagy and promote growth and metastasis in non-small cell lung cancer. Cell Death Differ, 2023, 30(2): 341-355.
68. Liu X, Ali MK, Zhao L, et al. The emerging diagnostic and therapeutic roles of small nucleolar RNAs in lung diseases. Biomed Pharmacother, 2023, 161: 114519.
69. Bratkovič T, Božič J, Rogelj B. Functional diversity of small nucleolar RNAs. Nucleic Acids Res, 2020, 48(4): 1627-1651.
70. Ahmad S, Zhang XL, Ahmad A. Epigenetic regulation of pulmonary inflammation. Semin Cell Dev Biol, 2024, 154(Pt C): 346-354.
71. Hussain S, Tulsyan S, Dar SA, et al. Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy. Semin Cancer Biol, 2022, 83: 441-451.
72. Li P, Liu S, Du L, et al. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer. Clin Epigenetics, 2022, 14(1): 118.
73. He LX, Tang ZH, Huang QS, et al. DNA methylation: A potential biomarker of chronic obstructive pulmonary disease. Front Cell Dev Biol, 2020, 8: 585.
74. Aggarwal T, Wadhwa R, Thapliyal N, et al. Oxidative, inflammatory, genetic, and epigenetic biomarkers associated with chronic obstructive pulmonary disorder. J Cell Physiol, 2019, 234(3): 2067-2082.
75. Fang Y, Qu Y, Ji L, et al. Novel blood-based FUT7 DNA methylation is associated with lung cancer: Especially for lung squamous cell carcinoma. Clin Epigenetics, 2022, 14(1): 167.
76. Zhang G, Wang Z, Song P, et al. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. EPMA J, 2022, 13(4): 649-669.
77. Günes Günsel G, Conlon TM, Jeridi A, et al. The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nat Commun, 2022, 13(1): 1303.
78. Cheng D, He Z, Zheng L, et al. PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2. Onco Targets Ther, 2018, 11: 4869-4876.
79. Su Y, Han W, Kovacs-Kasa A, et al. HDAC6 Activates ERK in airway and pulmonary vascular remodeling of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 2021, 65(6): 603-614.
80. Wattanathamsan O, Chantaravisoot N, Wongkongkathep P, et al. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction. J Biomed Sci, 2023, 30(1): 4.
81. Zhao L, Luo JL, Ali MK, et al. The human respiratory microbiome: Current understandings and future directions. Am J Respir Cell Mol Biol, 2023, 68(3): 245-255.
82. 木亚莎尔·吐逊江, 王雨琳, 曹洪丽. 慢性阻塞性肺疾病合并肺癌共同发病机制. 中国组织化学与细胞化学杂志, 2022, 31(4): 412-416.Muyashaer TXJ, Wang YL, Cao HL. The common pathogenesis of chronic obstructive pulmonary disease with lung cancer. Chin J Histochem Cytochem, 2022, 31(4): 412-416.
83. Liang W, Yang Y, Gong S, et al. Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease. Cell Host Microbe, 2023, 31(6): 1054-1070.
84. Madapoosi SS, Cruickshank-Quinn C, Opron K, et al. Lung microbiota and metabolites collectively associate with clinical outcomes in milder stage chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2022, 206(4): 427-439.
85. Cameron SJS, Lewis KE, Huws SA, et al. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One, 2017, 12(5): e0177062.
86. Kong LY, Chen XY, Lu X, et al. Association of lung-intestinal microecology and lung cancer therapy. Chin Med, 2023, 18(1): 37.
87. Wang W, Liang X, Kong H, et al. Correlation analysis of lung mucosa-colonizing bacteria with clinical features reveals metastasis-associated bacterial community structure in non-small cell lung cancer patients. Respir Res, 2023, 24(1): 129.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress on the pathogenesis of chronic obstructive pulmonary disease complicated with lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content